IL-17 Role in Variants of Psoriasis

You may not qualify if:

• Female subject is pregnant or lactating.
• Subject has used any topical treatment for psoriasis (except non medicated emollients) in the last 14 days before Day 0 with the exception of hydrocortisone and desonide for the face, groin (including genitals) and inframammary areas as well as shampoos containing tar, salicylic acid, or zinc pyrithione.
• Subject has used Ultra-Violet (UV) B phototherapy or excessive sun exposure less than 14 days before Day 0.
• Subject has used any non biological systemic therapy for the treatment of psoriasis (including Psoralen Ultra-Violet A (PUVA) therapy), systemic steroids or systemic immunosuppressants less than 28 days before Day 0. Investigational non biologics agents must be discontinued at least 28 days or 5 half lives prior to Day 0 (whichever is longer).
• Subject is currently participating in a clinical trial with an experimental drug or device.
• Subject who has used any biological therapy for the treatment of psoriasis less than 90 days before Day 0.
• Subject is taking or requires oral or injectable corticosteroids. Inhaled corticosteroids for stable medical conditions are allowed. Subjects who have used oral or injectable corticosteroids less than 28 days before Day 0 are excluded.
• Subject is known to have hepatitis B or hepatitis C viral infection.
• Subject is known to have immune deficiency or is immunocompromised or currently uses or plans to use anti retroviral therapy at any time during the study.
• Subject is taking anti-coagulant medication (v.g. heparin, LMW (low molecular weight)-heparin, warfarin, anti-platelets (NSAID and aspirin will not be considered anti-platelets)) or has a contra indication to skin biopsies.